New challenger in spinal implants : Bryan, Garnier & Co advises Spineart on €30M Equity Investment from Gimv
Share the transaction
Paris, September 22nd, 2016 – Bryan, Garnier & Co advised Spineart, the medical device company focused on orthopaedic surgery, on a €30m equity investment from Gimv, a healthcare specialist investor. Within the context of the financing process, led by Bryan, Garnier & Co, the bank raised interest from leading international investors. Gimv was chosen from amongst these investors for its ability to fully respond to Spineart’s ambitions: to accelerate its expansion in Europe and the US, penetrate new markets and develop its R & D projects.
With an ageing population, economic development in emerging countries and lifestyles with an increasing number of risks, the spinal market, with an estimated value of 10 billion dollars, is currently growing rapidly (+6.4% per year to 2020). Long dominated by established players in the spinal field, offering a large but not relatively innovative range of products, the market today has been shaken up by the arrival of new challengers such as Spineart.
Founded in 2005, Spineart creates and develops disruptive technologies for surgeons and patients (new forms of implants, different methods of implantation, innovative materials, etc.). A pioneer in its field, the company has long been experiencing rapid growth which enabled it to generate a global turnover of 34 million euros in 2015.
“Spineart perfectly fits the profile of the companies that Bryan, Garnier & Co advises: it is a European company, in the healthcare sector, experiencing fast growth in a flourishing market”, states Hervé Ronin, Partner at Bryan, Garnier & Co. The bank has followed Spineart for several years and accompanied the founders, managers and shareholders, throughout the fundraising process, alongside Société Générale, who also advised on this transaction. After having approached several investors, Bryan, Garnier & Co, Société Générale and Spineart selected Gimv, a healthcare specialist investor, to be the partner of choice to accompany the company’s ambitions.
Jérôme Lévieux and Stéphane Mugnier-Jacob, co-founders and co-CEOs of Spineart commented: “Bryan Garnier’s team demonstrated strong commitment throughout the process. Their deep expertise and understanding of our business and industries have been instrumental in raising interest from investors, leading to the successful completion of this transaction.”
Hervé Ronin, Partner at Bryan, Garnier & Co, added: “We are delighted to support Spineart, one of the most dynamic orthopaedic companies in Europe, in this financing round. This transaction illustrates once more the unique ability of Bryan, Garnier & Co to support European growth companies in the healthcare sector, in their various financial needs”.
Participants
Spineart: Jérôme Lévieux, Stéphane Mugnier-Jacob, Jérôme Ventura
Bryan, Garnier & Co: Hervé Ronin, Jean de Pracomtal
About Spineart
Spineart is a privately held medical device company focused on simplifying the surgical act by designing, developing and promoting safe and efficient solutions to spine surgeons, operating room teams, and patients. Spineart is a pioneer in its field, having introduced unique patented and clinically validated technologies in the fields of Minimally Invasive Surgery, Motion Preservation, Fusion, Biologics, and Fractures Treatment. Spineart markets a complete portfolio combining traceable barcoded sterile packed implants with compact instrument sets, thus proudly promoting greater safety, cost-efficiency, and compliance at the hospital. Founded in 2005, Spineart addresses 7 countries (of which the US) via direct sales and 39 countries through distributors across EMEA, Asia and Latin America.